K-LEASE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover K-lease, and when can generic versions of K-lease launch?
K-lease is a drug marketed by Savage Labs and is included in two NDAs.
The generic ingredient in K-LEASE is potassium chloride. There are two hundred and forty drug master file entries for this compound. Eighty-nine suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for K-lease
A generic version of K-LEASE was approved as potassium chloride by ACTAVIS LABS FL INC on April 10th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for K-LEASE?
- What are the global sales for K-LEASE?
- What is Average Wholesale Price for K-LEASE?
Summary for K-LEASE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 314 |
Patent Applications: | 2,336 |
Formulation / Manufacturing: | see details |
DailyMed Link: | K-LEASE at DailyMed |
![K-LEASE drug patent expirations Drug patent expirations by year for K-LEASE](/p/graph/s/t/K-LEASE-patent-expirations.png)
US Patents and Regulatory Information for K-LEASE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Savage Labs | K-LEASE | potassium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 073398-001 | Jan 28, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Savage Labs | K-LEASE | potassium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 072427-001 | Mar 28, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |